Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives as RAF-MEK-ERK pathway signaling pathway blockers: Synthesis, cytotoxic activity, mechanistic investigation and structure-activity relationships
作者:Qian Xie、Yanni Shen、Yanli Meng、Jianhui Liang、Jing Xu、Shishao Liang、Xiaoping Liu、Yan Wang、Chun Hu
DOI:10.1016/j.ejmech.2022.114579
日期:2022.10
often appears to re-enhance ERK1/2 signaling. Here we report the design, synthesis, biological activity of a series of novel pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives based on compound 1. Among them, the target compound N-(3-chlorophenyl)-2-((1,3-dimethyl-7-(4-methylpiperazin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)amino)acetamide (14m) exhibited excellent antiproliferative
ERK1/2(RAF-MEK-ERK)信号通路的组成型激活已在多种肿瘤中广泛观察到,并且已证明阻断ERK1/2信号通路可减少肿瘤生长。因此,ERK1/2信号通路已成为癌症治疗的一个有趣的治疗靶点。尽管 BRAF 和 MEK 抑制剂在临床治疗中取得了成功,但耐药性通常会重新增强 ERK1/2 信号传导。在这里,我们报告了一系列基于化合物1的新型吡啶并[2,3- d ]嘧啶-2,4(1 H ,3 H )-二酮衍生物的设计、合成和生物活性。其中,目标化合物N-(3-氯苯基)-2-((1,3-二甲基-7-(4-甲基哌嗪-1-基)-2,4-二氧代-1,2,3,4-四氢吡啶并[2,3- d ]pyrimidin-5-yl)amino)acetamide ( 14m ) 对 MCF-7、A375、SK-MEL-2 和 SK-HEP-1 细胞表现出优异的抗增殖活性,在 C28/I2 细胞中具有低细胞毒性。肿瘤球体测定显示14m在抑制